

# Global Tumor Immune Checkpoint Inhibitor Therapy Market Growth 2024-2030

<https://marketpublishers.com/r/GD9DF1F6D92FEN.html>

Date: August 2024

Pages: 112

Price: US\$ 3,660.00 (Single User License)

ID: GD9DF1F6D92FEN

## Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Immune checkpoint inhibitors are some monoclonal antibody drugs developed for the corresponding immune checkpoints. inhibition

The global Tumor Immune Checkpoint Inhibitor Therapy market size is projected to grow from US\$ 52240 million in 2023 to US\$ 91280 million in 2030; it is expected to grow at a CAGR of 8.3% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the "Tumor Immune Checkpoint Inhibitor Therapy Industry Forecast" looks at past sales and reviews total world Tumor Immune Checkpoint Inhibitor Therapy sales in 2023, providing a comprehensive analysis by region and market sector of projected Tumor Immune Checkpoint Inhibitor Therapy sales for 2024 through 2030. With Tumor Immune Checkpoint Inhibitor Therapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Tumor Immune Checkpoint Inhibitor Therapy industry.

This Insight Report provides a comprehensive analysis of the global Tumor Immune Checkpoint Inhibitor Therapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Tumor Immune Checkpoint Inhibitor Therapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Tumor Immune Checkpoint Inhibitor Therapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Tumor Immune Checkpoint Inhibitor Therapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Tumor Immune Checkpoint Inhibitor Therapy.

United States market for Tumor Immune Checkpoint Inhibitor Therapy is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Tumor Immune Checkpoint Inhibitor Therapy is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Tumor Immune Checkpoint Inhibitor Therapy is estimated to increase from US\$ million in 2023 to US\$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Tumor Immune Checkpoint Inhibitor Therapy players cover AstraZeneca, Bristol-Myers Squibb, Roche Holdings AG, Novartis AG and Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Tumor Immune Checkpoint Inhibitor Therapy market by product type, application, key manufacturers and key regions and countries.

#### Segmentation by type

PD-1/PD-L1

CTLA-4

#### Segmentation by application

Hospital

Clinic

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

AstraZeneca

Bristol-Myers Squibb

Roche Holdings AG

Novartis AG

Pfizer

Sanofi

Merck

Ono Pharmaceutical

Regeneron

Innovent

### Key Questions Addressed in this Report

What is the 10-year outlook for the global Tumor Immune Checkpoint Inhibitor Therapy market?

What factors are driving Tumor Immune Checkpoint Inhibitor Therapy market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Tumor Immune Checkpoint Inhibitor Therapy market opportunities vary by end market size?

How does Tumor Immune Checkpoint Inhibitor Therapy break out type, application?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
  - 2.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Sales 2019-2030
  - 2.1.2 World Current & Future Analysis for Tumor Immune Checkpoint Inhibitor Therapy by Geographic Region, 2019, 2023 & 2030
  - 2.1.3 World Current & Future Analysis for Tumor Immune Checkpoint Inhibitor Therapy by Country/Region, 2019, 2023 & 2030
- 2.2 Tumor Immune Checkpoint Inhibitor Therapy Segment by Type
  - 2.2.1 PD-1/PD-L1
  - 2.2.2 CTLA-4
- 2.3 Tumor Immune Checkpoint Inhibitor Therapy Sales by Type
  - 2.3.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)
  - 2.3.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue and Market Share by Type (2019-2024)
  - 2.3.3 Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Type (2019-2024)
- 2.4 Tumor Immune Checkpoint Inhibitor Therapy Segment by Application
  - 2.4.1 Hospital
  - 2.4.2 Clinic
  - 2.4.3 Other
- 2.5 Tumor Immune Checkpoint Inhibitor Therapy Sales by Application
  - 2.5.1 Global Tumor Immune Checkpoint Inhibitor Therapy Sale Market Share by Application (2019-2024)
  - 2.5.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue and Market Share

by Application (2019-2024)

2.5.3 Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Application (2019-2024)

### **3 GLOBAL TUMOR IMMUNE CHECKPOINT INHIBITOR THERAPY BY COMPANY**

3.1 Global Tumor Immune Checkpoint Inhibitor Therapy Breakdown Data by Company

3.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Sales by Company (2019-2024)

3.1.2 Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Company (2019-2024)

3.2 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Revenue by Company (2019-2024)

3.2.1 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Company (2019-2024)

3.2.2 Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Company (2019-2024)

3.3 Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Company

3.4 Key Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Product Location Distribution

3.4.2 Players Tumor Immune Checkpoint Inhibitor Therapy Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

### **4 WORLD HISTORIC REVIEW FOR TUMOR IMMUNE CHECKPOINT INHIBITOR THERAPY BY GEOGRAPHIC REGION**

4.1 World Historic Tumor Immune Checkpoint Inhibitor Therapy Market Size by Geographic Region (2019-2024)

4.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Sales by Geographic Region (2019-2024)

4.1.2 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Revenue by Geographic Region (2019-2024)

4.2 World Historic Tumor Immune Checkpoint Inhibitor Therapy Market Size by

Country/Region (2019-2024)

4.2.1 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Sales by Country/Region (2019-2024)

4.2.2 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Revenue by Country/Region (2019-2024)

4.3 Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Growth

4.4 APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Growth

4.5 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Growth

4.6 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Growth

## **5 AMERICAS**

5.1 Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Country

5.1.1 Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024)

5.1.2 Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024)

5.2 Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Type

5.3 Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Region

6.1.1 APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Region (2019-2024)

6.1.2 APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue by Region (2019-2024)

6.2 APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Type

6.3 APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia



## 6.10 China Taiwan

## **7 EUROPE**

### 7.1 Europe Tumor Immune Checkpoint Inhibitor Therapy by Country

#### 7.1.1 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024)

#### 7.1.2 Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024)

### 7.2 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Type

### 7.3 Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Application

### 7.4 Germany

### 7.5 France

### 7.6 UK

### 7.7 Italy

### 7.8 Russia

## **8 MIDDLE EAST & AFRICA**

### 8.1 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy by Country

#### 8.1.1 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024)

#### 8.1.2 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024)

### 8.2 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Type

### 8.3 Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Application

### 8.4 Egypt

### 8.5 South Africa

### 8.6 Israel

### 8.7 Turkey

### 8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

### 9.1 Market Drivers & Growth Opportunities

### 9.2 Market Challenges & Risks

### 9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Tumor Immune Checkpoint Inhibitor Therapy

10.3 Manufacturing Process Analysis of Tumor Immune Checkpoint Inhibitor Therapy

10.4 Industry Chain Structure of Tumor Immune Checkpoint Inhibitor Therapy

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Tumor Immune Checkpoint Inhibitor Therapy Distributors

11.3 Tumor Immune Checkpoint Inhibitor Therapy Customer

## **12 WORLD FORECAST REVIEW FOR TUMOR IMMUNE CHECKPOINT INHIBITOR THERAPY BY GEOGRAPHIC REGION**

12.1 Global Tumor Immune Checkpoint Inhibitor Therapy Market Size Forecast by Region

12.1.1 Global Tumor Immune Checkpoint Inhibitor Therapy Forecast by Region (2025-2030)

12.1.2 Global Tumor Immune Checkpoint Inhibitor Therapy Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Tumor Immune Checkpoint Inhibitor Therapy Forecast by Type

12.7 Global Tumor Immune Checkpoint Inhibitor Therapy Forecast by Application

## **13 KEY PLAYERS ANALYSIS**

13.1 AstraZeneca

13.1.1 AstraZeneca Company Information

13.1.2 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

13.1.3 AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue,

## Price and Gross Margin (2019-2024)

### 13.1.4 AstraZeneca Main Business Overview

### 13.1.5 AstraZeneca Latest Developments

## 13.2 Bristol-Myers Squibb

### 13.2.1 Bristol-Myers Squibb Company Information

### 13.2.2 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Product

#### Portfolios and Specifications

### 13.2.3 Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)

### 13.2.4 Bristol-Myers Squibb Main Business Overview

### 13.2.5 Bristol-Myers Squibb Latest Developments

## 13.3 Roche Holdings AG

### 13.3.1 Roche Holdings AG Company Information

### 13.3.2 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Product

#### Portfolios and Specifications

### 13.3.3 Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)

### 13.3.4 Roche Holdings AG Main Business Overview

### 13.3.5 Roche Holdings AG Latest Developments

## 13.4 Novartis AG

### 13.4.1 Novartis AG Company Information

### 13.4.2 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

### 13.4.3 Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)

### 13.4.4 Novartis AG Main Business Overview

### 13.4.5 Novartis AG Latest Developments

## 13.5 Pfizer

### 13.5.1 Pfizer Company Information

### 13.5.2 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

### 13.5.3 Pfizer Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)

### 13.5.4 Pfizer Main Business Overview

### 13.5.5 Pfizer Latest Developments

## 13.6 Sanofi

### 13.6.1 Sanofi Company Information

### 13.6.2 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

13.6.3 Sanofi Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)

13.6.4 Sanofi Main Business Overview

13.6.5 Sanofi Latest Developments

13.7 Merck

13.7.1 Merck Company Information

13.7.2 Merck Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

13.7.3 Merck Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)

13.7.4 Merck Main Business Overview

13.7.5 Merck Latest Developments

13.8 Ono Pharmaceutical

13.8.1 Ono Pharmaceutical Company Information

13.8.2 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

13.8.3 Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)

13.8.4 Ono Pharmaceutical Main Business Overview

13.8.5 Ono Pharmaceutical Latest Developments

13.9 Regeneron

13.9.1 Regeneron Company Information

13.9.2 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

13.9.3 Regeneron Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Regeneron Main Business Overview

13.9.5 Regeneron Latest Developments

13.10 Innovent

13.10.1 Innovent Company Information

13.10.2 Innovent Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

13.10.3 Innovent Tumor Immune Checkpoint Inhibitor Therapy Sales, Revenue, Price and Gross Margin (2019-2024)

13.10.4 Innovent Main Business Overview

13.10.5 Innovent Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**



## List Of Tables

### LIST OF TABLES

Table 1. Tumor Immune Checkpoint Inhibitor Therapy Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)

Table 2. Tumor Immune Checkpoint Inhibitor Therapy Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)

Table 3. Major Players of PD-1/PD-L1

Table 4. Major Players of CTLA-4

Table 5. Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2019-2024) & (K Units)

Table 6. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)

Table 7. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Type (2019-2024) & (\$ million)

Table 8. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Type (2019-2024)

Table 9. Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Type (2019-2024) & (US\$/Unit)

Table 10. Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2019-2024) & (K Units)

Table 11. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2019-2024)

Table 12. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Application (2019-2024)

Table 13. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Application (2019-2024)

Table 14. Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Application (2019-2024) & (US\$/Unit)

Table 15. Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Company (2019-2024) & (K Units)

Table 16. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Company (2019-2024)

Table 17. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Company (2019-2024) (\$ Millions)

Table 18. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Company (2019-2024)

Table 19. Global Tumor Immune Checkpoint Inhibitor Therapy Sale Price by Company

(2019-2024) & (US\$/Unit)

Table 20. Key Manufacturers Tumor Immune Checkpoint Inhibitor Therapy Producing Area Distribution and Sales Area

Table 21. Players Tumor Immune Checkpoint Inhibitor Therapy Products Offered

Table 22. Tumor Immune Checkpoint Inhibitor Therapy Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Geographic Region (2019-2024) & (K Units)

Table 26. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share Geographic Region (2019-2024)

Table 27. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 28. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Geographic Region (2019-2024)

Table 29. Global Tumor Immune Checkpoint Inhibitor Therapy Sales by Country/Region (2019-2024) & (K Units)

Table 30. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country/Region (2019-2024)

Table 31. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country/Region (2019-2024) & (\$ millions)

Table 32. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country/Region (2019-2024)

Table 33. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024) & (K Units)

Table 34. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country (2019-2024)

Table 35. Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024) & (\$ Millions)

Table 36. Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country (2019-2024)

Table 37. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2019-2024) & (K Units)

Table 38. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2019-2024) & (K Units)

Table 39. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Region (2019-2024) & (K Units)

Table 40. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by

Region (2019-2024)

Table 41. APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue by Region (2019-2024) & (\$ Millions)

Table 42. APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Region (2019-2024)

Table 43. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2019-2024) & (K Units)

Table 44. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2019-2024) & (K Units)

Table 45. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024) & (K Units)

Table 46. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country (2019-2024)

Table 47. Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024) & (\$ Millions)

Table 48. Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country (2019-2024)

Table 49. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2019-2024) & (K Units)

Table 50. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2019-2024) & (K Units)

Table 51. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Country (2019-2024) & (K Units)

Table 52. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country (2019-2024)

Table 53. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue by Country (2019-2024) & (\$ Millions)

Table 54. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country (2019-2024)

Table 55. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Type (2019-2024) & (K Units)

Table 56. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales by Application (2019-2024) & (K Units)

Table 57. Key Market Drivers & Growth Opportunities of Tumor Immune Checkpoint Inhibitor Therapy

Table 58. Key Market Challenges & Risks of Tumor Immune Checkpoint Inhibitor Therapy

Table 59. Key Industry Trends of Tumor Immune Checkpoint Inhibitor Therapy

Table 60. Tumor Immune Checkpoint Inhibitor Therapy Raw Material



- Table 61. Key Suppliers of Raw Materials
- Table 62. Tumor Immune Checkpoint Inhibitor Therapy Distributors List
- Table 63. Tumor Immune Checkpoint Inhibitor Therapy Customer List
- Table 64. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Region (2025-2030) & (K Units)
- Table 65. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Region (2025-2030) & (\$ millions)
- Table 66. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Country (2025-2030) & (K Units)
- Table 67. Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 68. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Region (2025-2030) & (K Units)
- Table 69. APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Region (2025-2030) & (\$ millions)
- Table 70. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Country (2025-2030) & (K Units)
- Table 71. Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 72. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Country (2025-2030) & (K Units)
- Table 73. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Country (2025-2030) & (\$ millions)
- Table 74. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Type (2025-2030) & (K Units)
- Table 75. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Type (2025-2030) & (\$ Millions)
- Table 76. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Forecast by Application (2025-2030) & (K Units)
- Table 77. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Forecast by Application (2025-2030) & (\$ Millions)
- Table 78. AstraZeneca Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors
- Table 79. AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications
- Table 80. AstraZeneca Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)
- Table 81. AstraZeneca Main Business
- Table 82. AstraZeneca Latest Developments

Table 83. Bristol-Myers Squibb Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors

Table 84. Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

Table 85. Bristol-Myers Squibb Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 86. Bristol-Myers Squibb Main Business

Table 87. Bristol-Myers Squibb Latest Developments

Table 88. Roche Holdings AG Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors

Table 89. Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

Table 90. Roche Holdings AG Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 91. Roche Holdings AG Main Business

Table 92. Roche Holdings AG Latest Developments

Table 93. Novartis AG Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors

Table 94. Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

Table 95. Novartis AG Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 96. Novartis AG Main Business

Table 97. Novartis AG Latest Developments

Table 98. Pfizer Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors

Table 99. Pfizer Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

Table 100. Pfizer Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 101. Pfizer Main Business

Table 102. Pfizer Latest Developments

Table 103. Sanofi Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors

Table 104. Sanofi Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

Table 105. Sanofi Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 106. Sanofi Main Business

Table 107. Sanofi Latest Developments

Table 108. Merck Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors

Table 109. Merck Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

Table 110. Merck Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 111. Merck Main Business

Table 112. Merck Latest Developments

Table 113. Ono Pharmaceutical Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors

Table 114. Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

Table 115. Ono Pharmaceutical Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 116. Ono Pharmaceutical Main Business

Table 117. Ono Pharmaceutical Latest Developments

Table 118. Regeneron Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors

Table 119. Regeneron Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

Table 120. Regeneron Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 121. Regeneron Main Business

Table 122. Regeneron Latest Developments

Table 123. Innovent Basic Information, Tumor Immune Checkpoint Inhibitor Therapy Manufacturing Base, Sales Area and Its Competitors

Table 124. Innovent Tumor Immune Checkpoint Inhibitor Therapy Product Portfolios and Specifications

Table 125. Innovent Tumor Immune Checkpoint Inhibitor Therapy Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2019-2024)

Table 126. Innovent Main Business

Table 127. Innovent Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Tumor Immune Checkpoint Inhibitor Therapy
- Figure 2. Tumor Immune Checkpoint Inhibitor Therapy Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Growth Rate 2019-2030 (K Units)
- Figure 7. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth Rate 2019-2030 (\$ Millions)
- Figure 8. Tumor Immune Checkpoint Inhibitor Therapy Sales by Region (2019, 2023 & 2030) & (\$ Millions)
- Figure 9. Product Picture of PD-1/PD-L1
- Figure 10. Product Picture of CTLA-4
- Figure 11. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type in 2023
- Figure 12. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Type (2019-2024)
- Figure 13. Tumor Immune Checkpoint Inhibitor Therapy Consumed in Hospital
- Figure 14. Global Tumor Immune Checkpoint Inhibitor Therapy Market: Hospital (2019-2024) & (K Units)
- Figure 15. Tumor Immune Checkpoint Inhibitor Therapy Consumed in Clinic
- Figure 16. Global Tumor Immune Checkpoint Inhibitor Therapy Market: Clinic (2019-2024) & (K Units)
- Figure 17. Tumor Immune Checkpoint Inhibitor Therapy Consumed in Other
- Figure 18. Global Tumor Immune Checkpoint Inhibitor Therapy Market: Other (2019-2024) & (K Units)
- Figure 19. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2023)
- Figure 20. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Application in 2023
- Figure 21. Tumor Immune Checkpoint Inhibitor Therapy Sales Market by Company in 2023 (K Units)
- Figure 22. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Company in 2023
- Figure 23. Tumor Immune Checkpoint Inhibitor Therapy Revenue Market by Company

in 2023 (\$ Million)

Figure 24. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Company in 2023

Figure 25. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Geographic Region (2019-2024)

Figure 26. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Geographic Region in 2023

Figure 27. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales 2019-2024 (K Units)

Figure 28. Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue 2019-2024 (\$ Millions)

Figure 29. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales 2019-2024 (K Units)

Figure 30. APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue 2019-2024 (\$ Millions)

Figure 31. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales 2019-2024 (K Units)

Figure 32. Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue 2019-2024 (\$ Millions)

Figure 33. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales 2019-2024 (K Units)

Figure 34. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue 2019-2024 (\$ Millions)

Figure 35. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country in 2023

Figure 36. Americas Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country in 2023

Figure 37. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)

Figure 38. Americas Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2019-2024)

Figure 39. United States Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 40. Canada Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 41. Mexico Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 42. Brazil Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 43. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Region in 2023

Figure 44. APAC Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Regions in 2023

Figure 45. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)

Figure 46. APAC Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2019-2024)

Figure 47. China Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 48. Japan Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 49. South Korea Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 50. Southeast Asia Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 51. India Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 52. Australia Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 53. China Taiwan Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 54. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country in 2023

Figure 55. Europe Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country in 2023

Figure 56. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)

Figure 57. Europe Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2019-2024)

Figure 58. Germany Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 59. France Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 60. UK Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 61. Italy Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 62. Russia Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth

2019-2024 (\$ Millions)

Figure 63. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Country in 2023

Figure 64. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share by Country in 2023

Figure 65. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Type (2019-2024)

Figure 66. Middle East & Africa Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share by Application (2019-2024)

Figure 67. Egypt Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 68. South Africa Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 69. Israel Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 70. Turkey Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 71. GCC Country Tumor Immune Checkpoint Inhibitor Therapy Revenue Growth 2019-2024 (\$ Millions)

Figure 72. Manufacturing Cost Structure Analysis of Tumor Immune Checkpoint Inhibitor Therapy in 2023

Figure 73. Manufacturing Process Analysis of Tumor Immune Checkpoint Inhibitor Therapy

Figure 74. Industry Chain Structure of Tumor Immune Checkpoint Inhibitor Therapy

Figure 75. Channels of Distribution

Figure 76. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Forecast by Region (2025-2030)

Figure 77. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share Forecast by Region (2025-2030)

Figure 78. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share Forecast by Type (2025-2030)

Figure 79. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share Forecast by Type (2025-2030)

Figure 80. Global Tumor Immune Checkpoint Inhibitor Therapy Sales Market Share Forecast by Application (2025-2030)

Figure 81. Global Tumor Immune Checkpoint Inhibitor Therapy Revenue Market Share Forecast by Application (2025-2030)

## I would like to order

Product name: Global Tumor Immune Checkpoint Inhibitor Therapy Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/GD9DF1F6D92FEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GD9DF1F6D92FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970